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Abstract
Background: In mammals, sex determination is genetically controlled. The SRY gene, located on
Y chromosome, functions as the dominant genetic switch for testis development. The SRY gene is
specifically expressed in a subpopulation of somatic cells (pre-Sertoli cells) of the developing
urogenital ridge for a brief period during gonadal differentiation. Despite this tight spatiotemporal
expression pattern, the molecular mechanisms that regulate SRY  transcription remain poorly
understood. Sry expression has been shown to be markedly reduced in transgenic mice harboring
a mutant GATA4 protein (a member of the GATA family of transcription factors) disrupted in its
ability to interact with its transcriptional partner FOG2, suggesting that GATA4 is involved in SRY
gene transcription.
Results: Although our results show that GATA4 directly targets the pig SRY promoter, we did not
observe similar action on the mouse and human SRY promoters. In the mouse, Wilms' tumor 1
(WT1) is an important regulator of both Sry  and Müllerian inhibiting substance (Amh/Mis)
expression and in humans, WT1 mutations are associated with abnormalities of sex differentiation.
GATA4 transcriptionally cooperated with WT1 on the mouse, pig, and human SRY promoters.
Maximal GATA4/WT1 synergism was dependent on WT1 but not GATA4 binding to their
consensus regulatory elements in the SRY promoter and required both the zinc finger and C-
terminal regions of the GATA4 protein. Although both isoforms of WT1 synergized with GATA4,
synergism was stronger with the +KTS rather than the -KTS isoform. WT1/GATA4 synergism was
also observed on the AMH promoter. In contrast to SRY, WT1/GATA4 action on the mouse Amh
promoter was specific for the -KTS isoform and required both WT1 and GATA4 binding.
Conclusion:  Our data therefore provide new insights into the molecular mechanisms that
contribute to the tissue-specific expression of the SRY and AMH genes in both normal development
and certain syndromes of abnormal sex differentiation.
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Background
In eutherian mammals, the gene responsible for triggering
testis development, and hence male sex determination, is
SRY  (Sex Determining Region, Y chromosome) which
encodes a putative transcription factor containing a high
mobility group box DNA binding domain. SRY initiates
the male pathway by triggering the differentiation of Ser-
toli cells in the genital ridge, the precursor of the develop-
ing gonad. During normal mammalian development, the
tightly regulated spatiotemporal expression of SRY within
the indifferent genital ridges is required for testis determi-
nation to proceed. Deregulation of this expression, either
via insufficient SRY mRNA concentrations [1,2], delayed
SRY expression [3], expression of different SRY isoforms
[4], and/or the contribution of autosomal loci [5,6], can
result in partial or complete failure of testis determination
and the formation of ovotestes or ovaries within XY indi-
viduals. SRY expression is now described within the geni-
tal ridges of several eutherian mammals (reviewed in [7]).
In the mouse, Sry  mRNA is first detected by RT-PCR
within the somatic cells of the indifferent genital ridges of
male embryos at e10.5, with a peak of expression seen at
e11.5 followed by a dramatic extinction of expression by
e12.5 [8]. These results have been confirmed by in situ
hybridization [9] and at the protein level [10]. Expression
of the human SRY transcript is first seen within the indif-
ferent male genital ridge beginning at 41 to 44 days post
ovulation, corresponding to Carnagie stages 17–18 [11].
In contrast to the mouse, human SRY expression is main-
tained at low levels within the developing testes for the
remainder of gestation, a finding supported by immuno-
histochemistry results [11]. The genital ridge expression of
SRY  has now been additionally described for the pig,
sheep, dog and goat, and collectively reveals the initiation
of SRY transcription within the indifferent male genital
ridge followed by a gradual trailing off of expression more
similar to the human model of expression than to the
mouse model [12-16].
Although the essential functional role of SRY has been
established for some time [17], surprisingly very little is
known about the molecular mechanisms that regulate its
spatiotemporal expression. The ability of Wilms' tumor 1
(WT1) and the nuclear receptor steroidogenic factor 1
(NR5A1/SF-1/Ad4BP) to bind and transactivate the
human or pig SRY promoters has been demonstrated [18-
21], suggesting that these factors contribute to the tissue-
specific expression profile of SRY. Moreover, more recent
data have shown that the SRY-related factor SOX9 can also
transactivate the pig SRY promoter via a consensus SOX9
binding site about 205 bp upstream of the ATG transla-
tional start site [22]. After the SRY gene is turned on, testis
differentiation ensues; Sertoli cells organize into cord
structures that encircle immature germ cells termed gono-
cytes. At the same time, Leydig cells present in the intersti-
tium of the testicular cords differentiate and begin to
secrete testosterone. The next stage of male development
is sex differentiation, which takes the form of Müllerian
duct (female reproductive tract) regression and Wolffian
duct (male reproductive tract) development. These events
rely on two hormones produced by the fetal testis: testo-
sterone, secreted by Leydig cells, and Müllerian inhibiting
substance (AMH/MIS), produced by Sertoli cells. Absence
of AMH in humans causes persistent Müllerian duct syn-
drome, a form of pseudohermaphroditism characterized
by the retention of Müllerian duct structures.
The genital ridge expression of AMH is described in the
human (reviewed in [23]), as well as the mouse [8], pig
[14,24,25], sheep [12] and dog [26]. AMH expression is
restricted to the pre-Sertoli cells of the male genital ridge,
always after the initiation of SRY expression and commi-
tant to the time of histological testis cord formation. Once
AMH expression is initiated it continues to be expressed at
high levels for the duration of the gestational period. The
transcriptional regulation of the AMH gene has been stud-
ied in detail. Interestingly, several transcription factors
involved in primary sex determination (SF-1, WT1, SOX9
and GATA4) are also recruited as important regulators of
AMH transcription [27-31]. Much like SRY, however, our
understanding of how these factors work together to
direct the sex-specific expression of the AMH  gene
remains incomplete.
A common regulatory factor important for transcription
of the SRY and AMH genes is WT1. WT1 is a zinc finger
transcription factor having both DNA and RNA binding
properties [32,33]. There are at least 24 different WT1 iso-
forms due to alternative transcription start sites, RNA edit-
ing, and 2 alternative splicing sites. The first alternative
splicing site inserts or removes exon 5, which encodes a 17
amino acid segment upstream of the zinc fingers. The sec-
ond alternative splicing site, at the end of exon 9, inserts
or removes three amino acids (KTS) between zinc fingers
3 and 4. Previous studies have shown that WT1 isoforms
with or without the KTS tripeptide have distinct biological
functions, whereas the alternative splicing site exon 5 has
a modulatory role on WT1 function. Although WT1 was
first identified as a tumor-suppressant gene of Wilms'
tumor [34,35], subsequent studies revealed that WT1 is
also essential for embryonic development, especially the
kidney and gonads (reviewed in [34,36-38]). In humans,
WT1 gene mutations are responsible for two urogenital
diseases: Denys-Drash syndrome (DDS) and Frasier syn-
drome. DDS is caused by exonic point mutations in the
WT1  gene, and is characterized by mesangial sclerosis
with early kidney failure, high risk of Wilms' tumor, and
varying degrees of gonadal dysgenesis associated with
insufficient AMH production [39]. On the other hand,
Frasier syndrome, characterized by focal segmental sclero-BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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sis, delayed kidney failure and XY gonadal sex reversal, is
associated with heterozygous point mutations in intron 9
that cause a shift in the ratio of WT1 isoforms (+/-KTS)
towards the -KTS forms [40,41]. The importance of WT1
during gonad development has also be demonstrated by
Wt1-null mice, which lack kidneys, gonads, and adrenals
[42,43]. Moreover, mice lacking the WT1(+KTS) splice
variant show complete XY sex reversal and a dramatic
reduction in Sry expression [44]. Consistent with a role in
SRY and AMH transcription, in vitro studies have shown
that WT1(-KTS) can bind and activate the respective gene
promoters [19,45,46]. However, since WT1 starts to be
expressed in the developing gonadal primordium of the
mouse (e9.5–e10.5) somewhat before the Sry and Amh
genes are actually first turned on (e10.5–e12.5) [8,47],
and since WT1 is present in several organs where SRY and
AMH are not, other factors must cooperate with WT1. Due
to its overlapping expression pattern with WT1 in the
developing urogenital system [48], GATA4 is an interest-
ing candidate.
GATA4 is a member of the GATA family of zinc-finger
transcription factors that recognize the consensus nucle-
otide sequence WGATAR (called the GATA motif) in the
promoter region of target genes. In the mouse, GATA4 is
strongly expressed in the somatic cell population of the
developing gonad prior to and during the time of sex
determination [48]. This expression pattern coincides
with the SRY  and  AMH  genes [8,49], suggesting that
GATA4 plays a predominant role in their expression. This
hypothesis is supported by in vivo experiments, where
mice carrying a GATA4 mutation that disrupts its ability to
interact with its transcriptional partner FOG2, display
abnormal testis development [50]. On a molecular level,
this is apparently due to a significant reduction in Sry tran-
scription and a block in Sox9 and Amh expression [50,51].
Thus GATA4, much like WT1, appears to play a predomi-
nant role in both primary sex determination and sex dif-
ferentiation via SRY and AMH gene regulation. However,
since GATA4 is rather broadly expressed, and more specif-
ically, is found in tissues that do not express either SRY or
AMH, it too cannot account by itself for the tight spatio-
temporal expression of these genes. Interestingly, the
developing gonad is a location where GATA4 and WT1 co-
localize with both SRY and AMH [8,47-49]. In this study,
we provide the first molecular evidence that a physical
and functional cooperation between WT1 and GATA4
contributes to the transcriptional regulation of the SRY
and AMH gene promoters.
Results
Species-specific regulation of SRY promoter activity by 
GATA4
There are multiple consensus GATA regulatory motifs
within the first 2 kilobases of 5' flanking sequences of the
mouse, pig, and human SRY genes (Fig. 1A). Although
numerous GATA binding sites are present in the different
SRY promoters, they are not necessarily species conserved
which is to be expected as SRY 5' flanking sequences are
generally poorly conserved between mammals [52]. As
shown in Fig. 1B, we tested the ability of GATA4, at vary-
ing doses, to transactivate the SRY promoter from these
three species by transient transfection assays in the heter-
ologous HeLa epithelial cell line. HeLa cells do not
express GATA4 making it a convenient cell line model for
promoter regulation studies involving this factor. Of the
three species tested, the pig SRY promoter was the most
responsive to GATA4 with an activation of about 3-fold
(Fig. 1B, middle panel). This was followed by the mouse
Sry promoter which was activated by 2-fold in the pres-
ence of GATA4 (Fig. 1B, left panel). This 2-fold activation
approached significance but was not significant (P >
0.05). Interestingly, the human SRY promoter was not
activated by GATA4 (Fig. 1B, right panel), and this despite
the presence of multiple consensus GATA binding motifs
and the fact that GATA4 could be strongly overexpressed
in HeLa cells (Fig. 1C). Similar results were obtained in
other heterologous cell lines such as CV-1 fibroblasts
(data not shown). The absence or relatively weak ability of
GATA4 to activate the SRY promoter suggested that the
factor might not bind to SRY GATA motifs with high affin-
ity. However, EMSA analysis revealed the contrary. As
shown in Fig. 2, GATA4 was able to strongly bind to all
four GATA motifs of the proximal pig SRY promoter. Sim-
ilar results were obtained with the GATA binding ele-
ments of the mouse and human SRY promoters (data not
shown). Thus, the mechanism of GATA4 in SRY gene reg-
ulation is unlikely one of direct transcriptional activation
by GATA4 alone.
Transcriptional cooperation between GATA4 and WT1 on 
the SRY promoter
Although  SRY  5' flanking sequences are known to be
divergent in mammals [21,52], in addition to GATA regu-
latory motifs, 2 partially conserved WT1 binding sites are
present within the first 2 kb of 5' flanking sequences of the
mouse, pig, and human SRY  genes (Fig. 3A). The
sequences of the putative WT1 binding sites are shown in
Fig. 3B. The TCC repeat elements common to the mouse,
pig, and human SRY sequences have been shown to be
recognized by both the -KTS and +KTS isoforms of WT1
[53]. The only exception is the human WT1 binding site 1
(5'-GAGGGGGTG-3') which appears to be preferentially
recognized by WT1(-KTS) and not WT1(+KTS) [19]. The
WT1 isoforms, much like GATA4, were capable of activat-
ing the SRY promoter on their own; the magnitude of the
activations, however, was greater than GATA4 being on
the order of 10–20 fold (Fig. 3D, open bars). Since the
WT1 and GATA binding elements lie in close proximity to
one another, we tested whether GATA4 could transcrip-BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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Transcriptional properties of GATA4 on the mouse, pig, and human SRY promoters Figure 1
Transcriptional properties of GATA4 on the mouse, pig, and human SRY promoters. A. Multiple consensus (but 
not species conserved) GATA binding motifs are present in the first 2 kilobases of the mouse, human, and pig SRY promoters; 
the GATA sites are indicated by the lozenges. B. Ability of GATA4 to transactivate the SRY promoter. HeLa cells were co-
transfected with either a -1090 bp mouse, -1400 bp pig, or -1250 bp human SRY-luciferase promoter construct (500 ng) along 
with increasing amounts of a GATA4 expression vector (25, 50, or 100 ng). All promoter activities are reported as fold activa-
tion over control ± S.E.M. Like letters indicate no statistically significant difference between groups (P > 0.05). C. Western blot 
analysis of nuclear extracts (10 µg) from HeLa cells overexpressing GATA4.BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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tionally cooperate with WT1 on the SRY promoter by per-
forming co-transfection experiments in heterologous
HeLa cells (Fig. 3D, black bars). The three species-specific
SRY  promoter constructs used in the co-transfection
experiments contained both WT1 binding sites and 4 or
more consensus GATA elements. On the mouse Sry pro-
moter, both WT1 isoforms strongly synergized with
GATA4 with activations reaching 30-fold (Fig. 3D, left
panel). Interestingly, the level of GATA4/WT1 synergism
was higher with WT1(+KTS) than with WT1(-KTS). Simi-
lar results were also observed on the pig SRY promoter
where activations reached nearly 50-fold (Fig. 3D, middle
panel), as well as in other cell lines such as TM4 mouse
Sertoli cells (data not shown). In contrast to the mouse
and pig, the human SRY promoter was strongly activated
by WT1(-KTS) alone and synergism with GATA4 only
occurred with the WT1(+KTS) isoform (Fig. 3D, right
panel). Western blot analysis confirmed the heterologous
nature of HeLa cells since they are null for both GATA4
and WT1 (Fig. 3C). It also showed that the GATA4/WT1
synergism was not due to variable expression of either
GATA4 or the WT1 isoforms since all proteins (whether
expressed individually or in combination) were present at
similar levels when overexpressed in HeLa cells (Fig. 3C).
The proximal WT1 binding site is essential for GATA4/WT1 
synergism on the mouse Sry promoter
To assess the binding site requirements for transcriptional
synergism between GATA4 and WT1, mouse Sry promoter
deletion and mutation constructs were prepared and used
in co-transfection assays (Fig. 4A). Interestingly, the -340
bp Sry promoter construct (containing an intact proximal
WT1 site and no consensus GATA sites) was synergistically
activated by GATA4 and WT1 to the same extent as the
full-length (-1090 bp) Sry  construct. This suggests that
GATA4 binding to its consensus sites on the Sry promoter
is dispensable for maximal synergism with WT1. Deletion
or mutation of the proximal WT1 site, however, abolished
the activation by WT1 alone and markedly decreased the
synergism between GATA4 and WT1 (Fig. 4A). Thus, in
contrast to GATA4, binding of WT1 to its consensus ele-
ment is critical for GATA4/WT1 synergism on the mouse
Sry promoter. Interestingly, GATA4/WT1 synergism was
not completely abrogated with the WT1 mutant con-
structs. The remaining synergism is likely due to two low
affinity (not perfect consensus) GATA binding motifs
present within the -340 to -70 bp sequence since a further
deletion to -40 bp eliminated all WT1/GATA4 synergism
(Fig. 4A). These two GATA motifs, named sites A
(GTATCT) and B (GTATCT), are unique to the mouse Sry
promoter sequence. Although these sites only weakly bind
GATA4 protein (Fig. 4B), they are nonetheless functional
as revealed by transfection assay (Fig. 4C). The remaining
GATA4/WT1 synergism observed on the -340 bp Sry con-
struct harboring the WT1 site mutation (-340 bp WT1
mut.) was abolished when a truncated wild-type GATA4
protein (aa 201–440) was substituted with two GATA4
mutants (C294A or ∆T279) that we have previously
shown to be unable to bind to DNA [54]. Thus, GATA4
binding to these two low affinity GATA motifs likely con-
tributes to the observed GATA4/WT1 synergism on the
mouse Sry promoter. We still cannot rule out the possibil-
ity, however, of additional unknown regulatory elements
(present between -340 and -70 bp) that might be indi-
rectly activated by GATA4/WT1 overexpression in our het-
erologous HeLa cell line model.
In a DNA-binding experiment (Fig. 5A), WT1 (+ or - KTS)
binding to a known consensus WT1 probe was competed
using either unlabeled probe or an oligonucleotide corre-
sponding to the proximal WT1 element (site 1) of the
mouse Sry promoter. Thus, these results demonstrate that
the proximal WT1 site (site 1) is efficiently bound by both
WT1 isoforms. The functional importance of the proximal
WT1 binding site was confirmed using homologous (WT1
and GATA4-expressing) PGR 9E11 cells, a pig genital ridge
cell line [21]. As shown in Fig. 5B, PGR cells express abun-
dant WT1 and GATA4 proteins. Transfection studies car-
ried out in this cell line clearly showed that the deletion or
mutation of the proximal WT1 element reduced Sry pro-
SRY promoter GATA motifs bind GATA4 Figure 2
SRY promoter GATA motifs bind GATA4. An EMSA 
was performed with recombinant GATA4 protein and a 32P-
labeled oligonucleotide probe corresponding to the first con-
sensus GATA motif (GATA site 1) of the pig SRY promoter. 
Competition with an oligonucleotide containing a mutated 
GATA motif (GATA to GGTA) was used to confirm the spe-
cificity of GATA4 binding (GATAmut site 1). GATA4 binding 
to the more distal GATA motifs (GATA sites 2–4) was then 
assessed by competition experiments using the indicated oli-
gonucleotides.BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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GATA4 and WT1 transcriptionally cooperate to activate the SRY promoter Figure 3
GATA4 and WT1 transcriptionally cooperate to activate the SRY promoter. A. In addition to multiple GATA 
motifs, two potential WT1 binding sites (indicated by gray circles) are present in the first 2 kilobases of the mouse, human, and 
pig SRY promoters. B. Nucleotide sequence of the potential WT1 binding sites in the mouse, pig, and human SRY promoters. C. 
Western blot analysis of HeLa cells extracts (10 µg) overexpressing GATA4 and/or WT1 (+/- KTS) isoforms. D. WT1 and 
GATA4 transcriptionally cooperate. HeLa cells were co-transfected with either a -1090 bp mouse, -1400 bp pig, or -1250 bp 
human SRY-luciferase promoter construct (500 ng) along with an empty vector or expression vectors (500 ng) for WT1(-KTS) 
or WT1(+KTS) in the absence (-) or presence (+) of GATA4 (50 ng). All promoter activities are reported as fold activation 
over control ± S.E.M. Like letters indicate no statistically significant difference between groups (P > 0.05).BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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The mouse Sry promoter requires an intact proximal WT1 binding site for full transcriptional synergism by GATA4 and WT1 Figure 4
The mouse Sry promoter requires an intact proximal WT1 binding site for full transcriptional synergism by 
GATA4 and WT1. A. Deletion and mutation analysis of mouse Sry 5' flanking sequences in HeLa cells. HeLa cells were co-
transfected with the different mouse Sry promoters (500 ng) as indicated along with an empty vector (control) or expression 
vectors for GATA4 and/or WT1(+KTS). B. The mouse Sry promoter contains two low affinity GATA binding elements (named 
sites A and B) located between -340 and -70 bp. An EMSA was performed with recombinant GATA4 protein and a 32P-labeled 
oligonucleotide probe corresponding to the consensus GATA element from the proximal murine Star promoter [70]. Compe-
tition with unlabeled probe (self) and oligonucleotides corresponding to GATA sites A and B of the mouse Sry promoter was 
used to assess the affinity of GATA4 binding to these sites. C. The low affinity GATA binding sites (A and B) of the proximal 
mouse Sry promoter are functional. The remaining GATA4/WT1 synergism observed on the -340 bp Sry construct harboring 
the WT1 site mutation (-340 bp WT1 mut.) is abolished when two different GATA4 DNA-binding mutants (C294A or ∆T279) 
are used. For the wild-type and mutated GATA4 constructs, a truncated GATA4 protein (aa 201–440; see diagram in Fig. 6A) 
was used. For all transfection experiments, promoter activities are reported as fold activation over control ± S.E.M. Like let-
ters indicate no statistically significant difference between groups (P > 0.05).BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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The proximal WT1 binding site in mouse Sry promoter is functional Figure 5
The proximal WT1 binding site in mouse Sry promoter is functional. A. A DNA-binding assay was performed with in 
vitro produced WT1 proteins and a 32P-labeled oligonucleotide probe corresponding to the consensus WT1 binding site of the 
human AMH promoter. WT1 binding (+ or - KTS isoforms) to the labeled probe was blocked by 10-fold excess of unlabeled 
probe (self) and unlabeled oligo corresponding to the proximal WT1 site (site 1) of the mouse Sry promoter. B. Western blot 
analysis of nuclear extracts (10 µg) from PGR 9E11 cells (a pig genital ridge cell line) using antisera against WT1 and GATA4. 
Nuclear extracts from HeLa cells overexpressing WT1(-KTS) and MA-10 Leydig cells were used as positive controls for WT1 
and GATA4 expression, respectively. C. Transfection studies performed in homologous PGR cells confirm the importance of 
the proximal WT1 site for basal Sry promoter activity. PGR cells were transfected with the deleted or mutated mouse Sry pro-
moter constructs (500 ng) as indicated. Results are shown as % activity relative to the intact -340 bp construct ± S.E.M. Like 
letters indicate no statistically significant difference between groups (P > 0.05). D. GATA4 is associated with the SRY promoter 
in PGR genital ridge cells. PGR cell lysates were prepared and interaction of GATA4 with the endogenous pig SRY promoter 
was studied by ChIP. An aliquot of chromatin preparation before immunoprecipitation (20% input) was used as positive con-
trol. Chromatin was precipitated with a GATA4 antiserum (αGATA4) or incubated with goat-IgG (IgG) which served as a neg-
ative control. A 320-bp DNA fragment spanning a portion of the SRY promoter containing the proximal WT1 binding site 
(ChIP targeting region 2) was amplified by PCR as indicated by the arrow. A more distal SRY promoter fragment lacking this 
WT1 site (ChIP targeting region 1) was not amplified.BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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moter activity to the same level as the minimal promoter
(approximately 33% of the intact construct; Fig. 5C).
Thus, WT1 binding to its proximal site is crucial for full
basal activity of the Sry promoter. In our Sry promoter
deletion experiments (Fig. 4A), we found that GATA bind-
ing to its consensus motifs was dispensable for maximal
GATA4/WT1 synergism suggesting that GATA4 cooperates
with DNA-bound WT1. As shown in Fig. 5D, a ChIP assay
using pig PGR cells confirmed that GATA4 is indeed asso-
ciated with the endogenous SRY promoter in close prox-
imity to the proximal WT1 binding site (ChIP targeting
region 2). In contrast, a more distal SRY promoter frag-
ment lacking the critical WT1 site (ChIP targeting region
1) could not be amplified.
The zinc finger domains and the C-terminal region of 
GATA4 are required for the transcriptional cooperation 
and physical interaction with WT1
The strong transcriptional cooperation between GATA4
and WT1 on the SRY promoter suggests that both factors
contact each other through a direct protein-protein inter-
action. The essential nature of this interaction is all the
more evident given that GATA4 binding to its consensus
motifs is not required for maximal synergism with WT1
(Fig. 4A). To map the domains of the GATA4 protein that
interact with WT1 and are important for synergism on the
Sry promoter, a series of truncated GATA4 proteins were
constructed as depicted in Fig. 6A. The GATA4 protein
contains two independent activation domains that flank
its DNA-binding domain. Deletion of the N-terminal
region (aa 1–200) had no significant effect on the tran-
scriptional synergism between GATA4 and WT1(+KTS)
(Fig. 6A). However, GATA4/WT1 synergism was lost using
proteins consisting solely of the N-terminal region (aa 1–
133), zinc finger region (aa 201–322) or C-terminal
domain (aa 302–440). Thus, the zinc finger and C-termi-
nal domains of the GATA4 protein are both required for
its ability to transcriptionally cooperate with WT1. Next,
the domain of the GATA4 protein involved in the direct
physical interaction with WT1 was mapped using in vitro
pull-down assays (Fig. 6B). Consistent with the transcrip-
tion data (Fig. 6A), the WT1 protein (- or +KTS) could
physically interact with the intact (wild-type) GATA4 pro-
tein (Fig. 6B, far left panel) but not with mutant GATA4
proteins that removed the zinc fingers or C-terminal por-
tions of the protein (Fig. 6B, 3 rightmost panels). Thus,
the zinc finger and C-terminal domains of GATA4 are also
essential for the physical interaction with WT1. The ability
of GATA4 to interact with WT1 in the absence of DNA-
binding was further confirmed by a co-immunoprecipita-
tion experiment (Fig. 6C).
GATA4/WT1 transcriptional synergism also regulates 
activity of the AMH promoter
Since we found in the present study that GATA4 and WT1
could cooperate to regulate transcription from the SRY
promoter, we surmised that the expression of other
gonadal genes might also be modulated by this functional
cooperation. Another obvious target in the sex determina-
tion/sex differentiation pathway is the AMH gene since its
proximal promoter region contains species-conserved
binding elements for both GATA4 and WT1 [see Addi-
tional file 1]. Both factors are known regulators of AMH
transcription [45,48], which is mediated through their
direct association with the proximal AMH promoter as
shown by ChIP (ref. [45] and data not shown). To better
define the role of GATA4 as a transcriptional partner for
WT1 in the cell-specific and developmental regulation of
the AMH gene, we tested whether GATA4 and WT1 could
synergistically activate the AMH  promoter. In our co-
transfection experiments, we used the mouse -180 bp Amh
promoter which contains the GATA and WT1 binding
sites in their normal context, as well a series of synthetic
constructs containing either GATA and/or WT1 elements
placed upstream of the minimal Amh promoter (Fig. 7).
Although crucial for Amh  transcription  in vivo [50],
GATA4 by itself is a poor activator of the Amh promoter
(Fig. 7A). While WT1 alone weakly activated the Amh pro-
moter, and in contrast to the Sry promoter, only the -KTS
isoform was transcriptionally active. In the presence of
both proteins, however, a strong synergistic activation was
observed not only on the native -180 bp Amh promoter
but also a synthetic reporter consisting of two consensus
GATA motifs placed upstream of the minimal (-65 bp)
Amh promoter containing an intact WT1 binding element
(Fig. 7A and 7C). Finally, to assess the binding site
requirements for GATA4/WT1 synergism, mutations or
deletions of the Amh promoter were generated (Fig. 7B
and 7D). Although activation by GATA4 alone was
retained using a construct with intact GATA motifs but a
mutated WT1 element, GATA4/WT1 synergism was lost
(Fig. 7B). Similarly, no GATA4/WT1 synergism was
observed on a construct containing an intact WT1 binding
site but deleted of the GATA motifs (Fig. 7D). Thus, again
unlike the SRY  promoter, maximal GATA4/WT1 syner-
gism on the AMH promoter requires both GATA4 and
WT1 binding.
A mutated form of WT1 (WT1 R394W) that causes the 
retention of Müllerian ducts in humans fails to synergize 
with GATA4
There are several naturally occurring WT1 mutants known
to cause male pseudohermaphroditism with retention of
Müllerian ducts (reviewed in [55]). One of these mutants,
WT1 R394W, was shown to be a poor activator of the
AMH  promoter [45]. To better explain the molecular
mechanism behind the human phenotype associated withBMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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The zinc finger domains and C-terminal region of the GATA4 protein are required for the transcriptional cooperation and  direct interaction with WT1 Figure 6
The zinc finger domains and C-terminal region of the GATA4 protein are required for the transcriptional 
cooperation and direct interaction with WT1. A. The domain of the GATA4 protein involved in the transcriptional 
cooperation with WT1 was identified using the full-length GATA protein and four different GATA4 deletion mutants as indi-
cated. HeLa cells were co-transfected with the -340 bp mouse Sry promoter (500 ng) along with an empty vector or expres-
sion vectors for the different GATA4 constructs in the absence (-) or presence (+) of a WT1(+KTS) expression vector (500 
ng). All promoter activities are reported as fold activation over control ± S.E.M. The dotted line indicates the activation 
induced by WT1(+KTS) alone. *, Significantly different from the activation elicited by WT1 alone (P < 0.05). B. In vitro pull-
down assays were performed using 500 ng of bacterially produced HIS-WT1(-KTS), HIS-WT1(+KTS) and HIS-LacZ fusion (-ve 
control) proteins and in vitro translated 35S-labeled GATA4 proteins. After extensive washes, the bound proteins were sepa-
rated on a 10% SDS-PAGE gel and visualized by autoradiography. Input corresponds to 10% of the total 35S-GATA4 used in 
each assay. C. GATA4 interacts with both WT1(-KTS) and WT1(+KTS) isoforms. HeLa cells were transfected with expression 
vectors for either GATA4 alone or GATA4 in the presence of WT1 (+ or -KTS isoforms). A 100-µg aliquot of nuclear extract 
was then immunoprecipitated (IP) with an antibody for WT1. The precipitated material was then subjected to Western blot 
(WB) analysis for GATA4. The nuclear extracts used in the IPs were also directly immunoblotted (2.5 µg per lane) to control 
for the specificity of the GATA4 and WT1 antisera.BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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the mutation, we were interested in verifying whether the
WT1 R394W mutant could still transcriptionally cooper-
ate with GATA4. As shown in Fig. 8, the WT1 R394W
mutant, unlike its wild-type counterpart (- or + WT1 iso-
forms), not only failed to activate the Amh promoter but
also failed to synergize with GATA4. This lack of syner-
gism was not related to the stability or expression level of
the mutant protein (data not shown). Rather, the lack of
synergism is most likely attributable to a decrease in DNA
binding affinity of the mutant WT1 protein for its binding
element [45]. This result therefore supports our previous
observation that GATA4/WT1 synergism on the AMH pro-
Transcriptional synergism between GATA4 and WT1 on the  Amh promoter requires GATA4 and WT1 binding to their  respective regulatory elements Figure 7
Transcriptional synergism between GATA4 and 
WT1 on the Amh promoter requires GATA4 and 
WT1 binding to their respective regulatory ele-
ments. A. The native -180 bp Amh promoter containing the 
GATA and WT1 elements in their natural context. B. A syn-
thetic reporter containing two consensus GATA motifs 
upstream of the minimal Amh promoter with its WT1 binding 
site mutated. C. A synthetic reporter containing two consen-
sus GATA motifs upstream of the minimal Amh promoter 
with an intact WT1 binding site. D. The minimal Amh pro-
moter containing only a WT1 binding site. In all experiments, 
HeLa cells were co-transfected with the different promoter 
constructs (500 ng) along with an empty vector or expres-
sion vectors for the WT1(-KTS) (500 ng) and GATA4 (100 
ng) used alone or in combination. All promoter activities are 
reported as fold activation over control ± S.E.M. Like letters 
indicate no statistically significant difference between groups 
(P > 0.05).
A mutated form of WT1 (WT1 R394W) that causes reten- tion of Müllerian ducts in humans fails to synergize with  GATA4 Figure 8
A mutated form of WT1 (WT1 R394W) that causes 
retention of Müllerian ducts in humans fails to syner-
gize with GATA4. A. HeLa cells were co-transfected with 
the mouse -180 bp Amh promoter and either an empty 
expression vector (control) or expression vectors for 
GATA4 (100 ng), WT1(-KTS) wild-type (500 ng) or WT1(-
KTS) R394W DDS mutant (500 ng), used alone or in combi-
nation as indicated. All promoter activities are reported as 
fold activation over control ± S.E.M. Like letters indicate no 
statistically significant difference between groups (P > 0.05).BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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moter absolutely requires binding of both factors to their
respective regulatory elements (Fig. 7). Thus, a failed tran-
scriptional synergism between GATA4 and the mutant
WT1 protein at the level of the AMH promoter could be a
contributing factor to the improper male sex differentia-
tion seen in WT1 R394W patients involving insufficient
AMH production.
Discussion
SRY is the genetic trigger for male sex determination in
mammals. Although its critical developmental function
has been established for more than 15 years now [17], the
molecular mechanisms that regulate its tight spatiotem-
poral expression in the developing genital ridge have
remained elusive. Although a number of transcriptional
regulators including SF-1, SOX9 and WT1 have been pro-
posed to participate in SRY  gene regulation [18,19,19-
21,46], the sum of these factors still do not explain its
highly restricted expression pattern. We report here, a
novel transcriptional cooperation between WT1 and the
GATA4 transcription factor. This important cooperation
not only markedly enhances transcription from the SRY
promoter but also targets the promoter of the AMH gene
involved in male sex differentiation. Thus, our data pro-
vide new insights into the molecular mechanisms that
control the tissue- and developmental-specific expression
of these two critical genes and identify GATA4 as a poten-
tial causative factor in cases of abnormal human sex devel-
opment such as Frasier syndrome (XY male-to-female sex
reversal with intact SRY  gene) and DDS syndrome
(incomplete sex differentiation associated with reduced
AMH levels).
In the mouse, GATA4 is strongly expressed in the somatic
cell population of the developing gonad prior to and dur-
ing the time of Sry expression [48]; GATA4 is also detected
in Sertoli cells of the early fetal testis in humans [56].
Moreover, more recent knockout data in the mouse
revealed that a functional GATA4 protein is required for
Sry expression and hence normal testis cord formation
[50], suggesting that GATA4 is essential for either the
onset or up-regulation of Sry transcription in the develop-
ing male genital ridge. Although the SRY promoters from
mouse, pig and human all contain multiple consensus
GATA regulatory motifs, only the mouse and especially
the pig SRY  5' flanking sequences were activated by
GATA4 (Fig. 1). This was not surprising knowing that
while SRY function is highly conserved across all mamma-
lian species, SRY promoter regulatory sequences are not.
Thus, it is entirely conceivable that GATA4 might directly
regulate SRY transcription in some mammalian species
(such as the pig and mouse) but not others (such as the
human). For these other species, GATA4 likely contributes
to SRY transcription through interactions with other tran-
scriptional regulators. Due to its implication in many clin-
ical cases of abnormal human sex development, an
interesting candidate for this GATA4-interacting factor is
WT1. Indeed, a previous study using transgenic mice
expressing green fluorescent protein (GFP) under the con-
trol of the Sry promoter has shown that Sry is expressed
only in somatic cells of the mouse genital ridge that also
co-express GATA4 and WT1 [57]. Consistent with its role
in SRY gene regulation, WT1 has been reported to activate
the SRY promoter [19,46]. Much like GATA4, however, it
alone cannot account for the highly restricted SRY expres-
sion pattern since WT1 is found in tissues where SRY is
not. Given the co-localization of GATA4 and WT1 in the
genital ridge, we surmised that both factors might cooper-
ate to regulate the SRY gene. Indeed, GATA4 strongly syn-
ergized with WT1 to activate the SRY promoter of all three
species tested (Fig. 3D). Thus, we propose that SRY expres-
sion is controlled by a GATA4/WT1 transcriptional coop-
eration rather than by the action of GATA4 or WT1 alone.
Although this mechanism helps us to better understand
the proper spatiotemporal expression of the SRY gene,
other factors must also participate. This includes SOX9,
SF-1, and especially FOG2. Fog2-null mice have disrupted
testicular development and markedly reduced Sry expres-
sion [50]. FOG2 was originally cloned as a cofactor for
GATA4 and this interaction is essential for normal testis
differentiation [50,51]. Although most in vitro studies
point to FOG2 acting as a co-repressor for GATA4 tran-
scriptional activity [58], whether this is actually the case in
vivo remains to be shown.
Our results provide strong evidence that both the WT1(-
KTS) and WT1(+KTS) isoforms act as transcriptional acti-
vators of the SRY promoter. It is generally accepted, how-
ever, that WT1(-KTS) functions as a transcriptional
regulator whereas WT1(+KTS) plays a role in other cellular
processes, such as RNA processing [59]. Indeed, to date,
only a few genes have been identified as potential tran-
scriptional targets of WT1(+KTS). For example, transacti-
vation of the CDH1 (cadherin 1/E-cadherin) gene, which
encodes a calcium-dependent cell adhesion protein, is
enhanced by WT1 (+KTS) through GC-rich and CAAT box
sequences [60]. Moreover, WT1(+KTS) can activate the
promoter of the human MYC (C-MYC) gene via two WT1
binding sites [61]. We found that the mouse Sry promoter
contains two possible WT1 binding sites, a distal site at -
940 bp (5'-GGAGGA-3') and a proximal one at -50 bp (5'-
GGAGGAGGGA-3') upstream of the transcription start
site. Their sequences are antisense to a TCC-repeat ele-
ment which has been identified as a binding motif for
both WT1(-KTS) and WT1(+KTS) [53]. Indeed, our results
showed that WT1(+KTS) binds to the proximal site (Fig.
5A) and activates mouse Sry promoter activity alone and
in association with GATA4 (Fig. 3D). Thus taken together,
although the target genes of WT1(+KTS) are limited in
comparison to WT1(-KTS), WT1(+KTS) nonethelessBMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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appears to be an important transcriptional regulator of the
SRY gene. This is not surprising given that the best known
human WT1 mutation associated with sex reversal (Fra-
sier syndrome) produces a shift in the WT1 +/-KTS ratio
that favors the -KTS isoform [40,41].
Interestingly, the level of GATA4/WT1 synergism on the
SRY promoter was much stronger when the WT1(+KTS)
isoform was used. Importantly, this observation might
improve our understanding of Sry regulation in mutant
mice as reported by Hammes et al. [44]. They showed that
mutant mice that express only WT1(-KTS) or WT1(+KTS)
have distinct functions in sex determination and gonad
development [44]. The mouse mutant lacking the
WT1(+KTS) isoform exhibited a reduction in Sry expres-
sion (less than 25% of wild-type) leading to a block in tes-
tis development. In contrast, the mouse mutant lacking
WT1(-KTS) still showed modest expression of male spe-
cific genes (Sox9 and Amh) downstream of Sry, suggesting
that WT1(+KTS), and not WT1(-KTS) is essential for Sry
expression and consequently normal testis development.
We show here that the level of GATA4/WT1(+KTS) syner-
gism on the mouse Sry promoter was more than twice that
of GATA4/WT1(-KTS). Thus, our findings suggest that the
reduction in Sry  expression seen in the mouse lacking
WT1(+KTS) might be the result of a lack of appropriate
GATA4/WT1(+KTS) synergism and hence, insufficient
activation of the Sry promoter. The importance of WT1 in
male sex determination has also been well-documented in
the human since several diseases have been shown to be
associated with WT1 mutations, such as DDS and Frasier
syndrome. Male-to-female sex reversal seen in patients
with Frasier syndrome is caused by heterozygous muta-
tions in exon 9 of WT1, which as previously mentioned,
results in reduced levels of the WT1(+KTS) isoform and an
concomitant increase in WT1(-KTS). Thus, WT1(+KTS) is
believed to be critical for testis determination in the
human as in the mouse. Contrary to these in vivo data,
however, previous reports [19,20], as well as our present
in vitro studies show that the human SRY promoter to be
comparatively less responsive to WT1(+KTS) than WT1(-
KTS). Despite this observation, we found that GATA4
enhances WT1(+KTS) action on the human SRY  pro-
moter; an effect that was not observed with the WT1(-
KTS) isoform (Fig. 3D), suggesting that WT1(+KTS) also
likely contributes to human SRY transcription in coopera-
tion with GATA4.
In the mouse, immediately after sex determination (testis
differentiation), male sex differentiation ensues with the
onset of Amh expression by the newly differentiated Ser-
toli cells. To date, four transcription factors, all acting
within the first 180 bp of 5' flanking sequences, have been
proposed to be involved in the sex-specific regulation of
the  Amh  gene: SF-1, WT1, SOX9, and GATA4 [27-31].
Based on several in vitro and in vivo studies [27-29], up-
regulation of Amh  gene expression in the fetal testis
appears to require the presence of both SF-1 and WT1.
Moreover, it has been reported that SOX9 binding to its
specific response element is essential for the initiation of
Amh transcription [27]. Studies from our group and oth-
ers have also shown GATA4 to be an important player in
AMH gene regulation [54,62,63]. We now show that the
WT1-dependent regulation of the Amh promoter, much
like the Sry promoter, is markedly enhanced by GATA4.
An important difference, however, was the promoter-spe-
cific response to the WT1 isoforms. Consistent with previ-
ous reports [29], WT1(-KTS) was the transcriptionally
active isoform on the Amh promoter (Fig. 7 and data not
shown). Thus, WT1(+KTS) and WT1(-KTS) appear to have
different actions on the SRY and AMH promoters as has
been described for other WT1 target genes involved in the
sex determination pathway [19,20,45,64].
Conclusion
Taken together, our data not only provide new insights
into the molecular mechanisms that contribute to the tis-
sue-specific expression of the SRY and MIS genes but also
highlight the importance of GATA4 a key regulator of
gonadal development by acting a two levels in the mam-
malian sex determination and differentiation cascade.
Methods
Plasmids
The mouse, pig and human SRY promoters were ampli-
fied by PCR using the corresponding species-specific
genomic DNA as template and the following pairs of
primers: mouse (forward: 5'-CGGGATCCGCTGTATTGT-
CAATAAAACAG-3', reverse: 5'-GGGGTACCGACAATTGT-
CACCAGTCCC-3'); pig (forward: 5'-
CGGGATCCTTTGAGTTCCAAGG-3', reverse: 5'-GGGG-
TACCGAAAAGGGGGAGGAAGCG-3'); human (forward:
5'-CGGGATCCAATTCATATAGCTTTTTGTGTCC-3',
reverse: 5'-GGGGTACCTCAACACCCCCTCAAC-3'). The
different promoters fragments were subsequently cloned
into the BamHI/KpnI site of a modified luciferase expres-
sion vector [65]. Deletion constructs for the mouse Sry
promoter were generated by PCR using the following pairs
of primers: -820 bp (forward: 5'-CGGGATCCGCCGTAG-
TAGACTATGATAC-3', reverse: 5'-GGGGTACCGACAATT-
GTCACCAGTCCC-3'); -340 bp (forward: 5'-
CGGGATCCCTTTCCACTACTTTTGCA-3', reverse: 5'-
GGGGTACCGACAATTGTCACCAGTCCC-3'); -40 bp (for-
ward: 5'-CGGGATCCTTACACACGTTAAATATTAAAATC-
3', reverse: 5'-GGGGTACCGACAATTGTCACCAGTCCC-
3'). Promoter fragments were then cloned into the luci-
ferase reporter as described above. The -340 mouse Sry
promoter construct with a specific deletion of the WT1
response element (∆WT1) was achieved by cloning a -340
to -70 bp Sry promoter fragment, obtained by PCR (for-BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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ward primer: 5'-CGGGATCCCTTTCCACTACTTTTGCA-3',
reverse primer: 5'-GAAGATCTCTAGTC-
CAGCCCAACTAATC-3'), in front of the minimal mouse
Sry promoter construct. A -340 bp mouse Sry promoter
construct harboring a mutation that inactivates the WT1
element (GGAGGAGGGA to GGTGTTGGGT) was gener-
ated using the QuikChange XL mutagenesis kit (Strata-
gene, La Jolla, CA) according to the manufacture's
recommendations along with the following oligonucle-
otides – sense: 5'-GACTAGGGAGGTCCTGAAGGTGTT-
GGGTTAAATATTTTCTTACAC-3'; antisense: 5'-
GTGTAAGAAAATATTTAACCCAACACCTTCAGGACCTC-
CCTAGTC-3'. The natural and synthetic murine Amh-luci-
ferase promoter constructs have been described
previously [31]. The synthetic Amh  promoter construct
containing a WT1 binding site mutation was generated by
site-directed mutagenesis using the following primer pair
– sense: 5'-TACAGCAAGGCCCGGGCGGCCCCGCT-
TATATGTA-3'; antisense: 5'-TACATATAAGCG-
GGGCCGCCCGGGCCTTGCTGTA-3'. Finally, the WT1(-
KTS) DDS (R394W) mutant was also made by site-
directed mutagenesis using the wild-type WT1 cDNA as
template and the following primers – sense: 5'-CTTCA-
GATGGTCGGACCAGGAAAACTTTCGCTG -3'; antisense:
5'-CAGCGAAAGTTTTCCTGGTCCGACCATCTGAAG-3'.
The GATA4 expression vectors (wild-type, deletions and
DNA-binding mutants) have been described previously
[31,54,62,66]. Expression vectors for the wild-type mouse
WT1 isoforms were kindly provided by Dr. Jerry Pelletier
(McGill University). All plasmid constructs were verified
by sequencing.
Cell culture and transfections
Pig genital ridge PGR 9E11 cells [21] were grown in
DMEM supplemented with 10% newborn calf serum at
37°C and 5% CO2. The human cervical carcinoma HeLa
cell line was maintained in 1:1 DMEM/Ham's F-12 con-
taining 10% fetal bovine serum. HeLa cells were trans-
fected in 24-well culture plates using the calcium
phosphate precipitation method [67]. PGR 9E11 cells
were seeded in 12-well plates and transfected using the
LipofectAMINE reagent (Invitrogen, Burlington, Canada).
In brief, 2.5 µg of SRY promoter-luciferase reporters were
transfected with 2.5 µl of LipofectAMINE reagent per well
in serum- and antibiotic-free media. A renilla (phRL-TK)
luciferase plasmid (Promega, Madison, WI) was used as
an internal control. Complete medium was added 5 h
after transfection. The next day, the cells were harvested
and analyzed using the Dual-Luciferase reporter assay sys-
tem from Promega. The data reported represent the aver-
ages of at least three experiments, each done in duplicate.
For the experiments presented herein, the internal control
was unaffected by either GATA4 or WT1 overexpression
[see Additional file 2].
Nuclear extracts and Western blots
Nuclear extracts were prepared by the procedure outlined
by Schreiber et al. [68]. In Western analyses, 10-µg aliq-
uots of nuclear extracts from untreated PGR 9E11 or trans-
fected HeLa cells with GATA4 and/or WT1 expression
vectors were separated by SDS-PAGE and then electro-
transferred to Hybond PVDF membranes (GE Healthcare
Life Sciences, Baie d'Urfé, Canada). Immunodetection of
the GATA4 protein was achieved using a GATA4 antise-
rum (catalog # sc-1237; Santa Cruz Biotechnology, Santa
Cruz, CA). WT1 proteins were detected using an anti-WT1
antibody (catalog # sc-192; Santa Cruz) and a
VECTASTAIN-ABC-Amp Western blot detection kit (Vec-
tor Laboratories Canada, Burlington, Canada). Duolux
(Vector) was used as chemiluminescent substrate.
DNA binding (EMSA) assays
To assess binding of GATA4 to the consensus GATA sites
in the pig SRY promoter, in vitro translated GATA4 pro-
tein was prepared using the TNT system from Promega.
DNA binding assays were performed using a 32P-labeled
double-stranded oligonucleotide corresponding to the
proximal GATA site (GATA site 1) of the pig SRY promoter
– sense oligo: 5'-GATCCGCCTTATTATCATAATAAA-3';
antisense oligo: 5'-GATCTTTATTATGATAATAAGGCG-3'.
Competition with an oligonucleotide containing a
mutated GATA motif (GATA to GGTA) was used to con-
firm the specificity of GATA4 binding – GATAmut site 1
(sense: 5'-GATCCGCCTTATTACCATAATAAA-3', anti-
sense: 5'-GATCTTTATTATGGTAATAAGGCG-3'). Compe-
tition experiments using a series of double-stranded
oligonucleotides were then used to confirm GATA4 bind-
ing to the more distal GATA motifs in the pig SRY pro-
moter – GATA site 2 (sense: 5'-
GATCCATTGGGTTATCTTGAATCA-3', antisense: 5'-
GATCTGATTCATGATAACCCAATG-3'); GATA site 3
(sense: 5'-GATCCACATACTGATAATCATCAA-3', anti-
sense: 5'-GATCTTGATGATTATCAGTATGTG-3'); GATA
site 4 (sense: 5'-GATCCCCAAGGTTATCTGTTTTTA-3',
antisense: 5'-GATCTAAAAACAGATAACCTTGGG-3').
Recombinant GATA4 protein was also used to assess the
affinity of GATA4 binding to two non-consensus GATA
motifs (named sites A and B) in the proximal mouse Sry
promoter. For this specific experiment, the consensus
GATA element of the proximal murine Star  promoter
(sense: 5'-GATCCACTTTTTTATCTCAAGTGA-3'; anti-
sense: 5'-GATCTCACTTGAGATAAAAAAGTG-3') was used
as labeled probe. Competition using oligos corresponding
to sites A (sense: 5'-GTTCTTTGTATCTTAATACT-3'; anti-
sense: 5'-AGTATTAAGATACAAAGAAC-3') and B (sense:
5'-CTTGACAGTATCTAGGTTCA-3'; antisense: 5'-TGAAC-
CTAGATACTGTCAAG-3') was used to assess the affinity
of GATA4 binding to these two sites. A similar approach
was used to demonstrate WT1 binding to the proximal
WT1 element in the mouse Sry promoter. In vitro trans-BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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lated WT1(-KTS) and WT1(+KTS) proteins were prepared
using the TNT system (Promega). WT1 binding assays
were performed using a 32P-labeled double-stranded oli-
gonucleotide corresponding to the distal WT1 element of
the human AMH promoter (sense oligo: 5'-GGATCACT-
GGGGAGGGAGATAGGA-3', antisense oligo: 5'-GATCTC-
CTATCTCCCTCCCCAGTG-3') which has been described
as a consensus binding site for both the -KTS and +KTS
isoforms of WT1 [20]. Competition experiments using a
double-stranded oligonucleotide corresponding to the
proximal WT1 site in mouse Sry promoter (sense oligo: 5'-
GGATCCTGAAGGAGGAGGGATAA-3', antisense oligo:
5'-GATCTTATCCCTCCTCCTTCAGG-3') was used to con-
firm WT1 binding to the Sry  promoter. For all EMSA
experiments, binding reactions and electrophoresis condi-
tions were as described previously [48].
Production of HIS fusion proteins
Recombinant histidine-tagged WT1 fusion proteins (HIS-
WT1) were obtained by cloning the coding region of the
mouse WT1 protein in-frame with HIS using the commer-
cially available pRSETB fusion protein vector from Invit-
rogen. The resulting construct was introduced into the
Escherichia coli strain BL21, and the fusion protein was
produced by inducing the bacterial culture with IPTG.
After induction, the bacterial culture was lysed by sonica-
tion and the fusion protein was purified using a TALON
metal affinity resin (BD Biosciences, Mississauga, Can-
ada) according to instructions outlined by the manufac-
turer.
In vitro pull-down assays
In vitro pull-down (protein-protein interaction) assays
were done using 35S-labeled in vitro translated GATA4
proteins (wild-type and deletion mutants) and the puri-
fied HIS-WT1 and HIS-LacZ fusion proteins coupled to
TALON metal affinity resin. The 35S-labeled GATA4 pro-
teins were obtained using the TNT system as described
above; the amino acid positions of the different GATA4
proteins used are given in Fig. 6A. Proteins were incubated
in 500 µl binding buffer (20 mM Hepes pH 7.9, 70 mM
KCl, 20% Glycerol, 0.5% Triton X-100) supplemented
with 0.01% BSA for 30 min at room temperature. Bound
immunocomplexes were washed three times in washing
buffer (60 mM NaH2PO4, 600 mM NaCl, 20% Glycerol,
0.75% Triton X-100), resuspended in Laemmli buffer, and
subjected to SDS-PAGE. Proteins were finally electrotrans-
ferred to Hybond PVDF membrane and visualized by
autoradiography.
Co-immunoprecipitation
Nuclear extracts were prepared from HeLa cells transfected
with expression vectors for GATA4 or a combination of
GATA4 and WT1. A 100-µg aliquot of each extract was
then immunoprecipitated overnight using the WT1 anti-
body in binding buffer as described previously [69].
Immunocomplexes were then collected by incubation
with 20 µl of protein G-Sepharose beads (GE Healthcare
Life Sciences) at 4°C for 1 h. Bound immunocomplexes
were washed four times with binding buffer, resuspended
in 30 µl of 1× Laemmli buffer, and subjected to SDS-
PAGE. Proteins were electrotransferred to PVDF mem-
brane and subjected to immunoblotting using a 1:1000
dilution of the GATA4 antibody and detected with the
Vectastain-ABC-Amp Western blot detection kit.
Chromatin immunoprecipitation (ChIP) assay
PGR cells (4 × 107) were cross-linked with 1% formalde-
hyde (final concentration) for 10 min at 37°C. The cells
were then washed 3 times with PBS, resuspended in ChIP
lysis buffer [1% SDS, 10 mM EDTA, and 50 mM Tris-HCl
(pH 8.0)], and incubated for 10 min at 4°C. The lysed
cells were sonicated on ice using a BRANSON 450 Sonica-
tor for 5 cycles of 30-sec pulses at 3.5 output control and
80% duty cycle in order to obtain DNA fragments
between 200 bp and 1000 bp in size. After centrifugation
of the solution for 10 min at 4°C, the supernatant was
precleared for 2 h at 4°C with 20 µl of a protein G-Sepha-
rose bead slurry (GE Healthcare Life Sciences) that had
been prepared by washing it 3 times with RIPA buffer [50
mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.1%
SDS, 0.5% Igepal CA-630 (Sigma-Aldrich Canada,
Oakville Canada)]. After centrifugation for 10 min at 4°C,
500 µl of supernatant was subjected to overnight incuba-
tion at 4°C with 0.4 µg anti-GATA4 or control goat IgG
(Santa Cruz) in immunoprecipitation buffer [20 mM Tris-
HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, 1% Triton X-
100]. The immunocomplexes were recovered by a 2 h
incubation with 20 µl protein G Sepharose beads. The pre-
cipitates were washed 5 times with 1 ml RIPA buffer, 5
times with 1 ml high salt RIPA buffer [50 mM Tris-HCl
(pH 8.0), 5 mM EDTA, 500 mM NaCl, 0.1% SDS, 0.5%
Igepal CA-630], 3 times with LiCl buffer (250 mM LiCl
and 0.1% Igepal CA-630), and finally twice with 1 ml of
TE buffer [10 mM Tris-HCl (pH 8.0), 1 mM EDTA]. Pro-
tein-DNA complexes were eluted from protein G Sepha-
rose beads by addition of elution buffer (1% SDS, 0.1 M
NaHCO3) and rotation at room temperature for 15 min.
Cross-links were reversed by addition of 200 mM of NaCl
and heating at 65°C for 4 h. Proteins were degraded using
proteinase K treatment (1 h at 55°C) and the DNA frag-
ments were purified using a QIAquick gel extraction kit
(Qiagen, Mississauga, Canada). PCR amplifications were
done using 1 µl of input chromatin sample and 5 µl of
GATA4-immunoprecipitated DNA sample with primers
specific for either the distal (ChIP region 1) pig SRY pro-
moter (forward primer: 5'-GTATTCACTTATTTCATTTGG-
TAAGCCA-3'; reverse primer: 5'-
CGAGGTGAACATAACACTTC-3') or the proximal (ChIP
region 2) pig SRY promoter (forward primer: 5'-TACT-BMC Molecular Biology 2008, 9:44 http://www.biomedcentral.com/1471-2199/9/44
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GGGGGCGGAGAAATTG-3'; reverse primer: 5'-
GGGTCGCTTGACACGATCCT-3'). PCR amplifications
were carried out at 94°C for 5 min, followed by 40 cycles
of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec,
and a final extension of 5 min at 72°C. The PCR products
were analyzed by electrophoresis on a 2% ethidium bro-
mide-stained agarose gel. ChIP results were confirmed by
at least 2 separate experiments.
Statistical Analysis
Statistical comparisons between multiple groups were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by a Student-Newman-Keuls test. Where normality
and/or equal variance among groups was not met, data
were analyzed by a Kruskal-Wallis ANOVA followed by a
Student-Newman-Keuls test to detect significant differ-
ences. P < 0.05 was considered significant. All statistical
analyses were done with the aid of the SigmaStat 3.5 soft-
ware package (Systat Software, Inc., Point Richmond, CA).
List of abbreviations
RT-PCR: reverse transcriptase-polymerase chain reaction;
EMSA: electrophorectic mobility shift assay; DMEM: Dul-
becco's modified Eagle's medium; IPTG: isopropyl-1-thio-
D-galactopyranoside; PVDF: polyvinylidene difluoride;
LacZ:  β-galactosidase; DDS: Denys-Drash syndrome;
ChIP: chromatin immunoprecipitation.; BSA: bovine
serum albumin.
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